GSK offers discount to win UK green light for platelet drug

LONDON (Reuters) – GlaxoSmithKline has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade, after offering a price discount to the country's state-run healthcare service. Revolade, also known as eltrombopag, was originally rejected in 2010 by the National Institute for Health and Clinical Excellence (NICE) as not cost-effective. Draft guidance published on Wednesday now recommends it for certain patients with chronic immune thrombocytopenic purpura, a bleeding disorder, following the discount offer from GSK. …